pcn poster

Posters

Hospitalizations, Emergency Room Visits and Adherence Among Patients With Schizophrenia Initiated on Long-Acting Injectable Versus Oral Antipsychotics: A Systematic Review and Meta-Analysis

Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have the potential to increase medication adherence in adult patients with schizophrenia. This increas...

Maria-Helene Lafeuille , MA;

Philippe Thomas-Leduc , MSc;

Isabelle Ghelerter ;

Patrick Lefebvre , MA;

Ha Nguyen , BA;

Dee Lin , PharmD, MS;

Panagiotis Mavros , PhD;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Onset of Reduction in Depressive Symptoms in Postpartum Depression (PPD): Pivotal Studies of Two Neuroactive Steroid GABAA Receptor Positive Allosteric Modulators, Brexanolone Injection and Zuranolone

Background: Brexanolone injection (BRX) and the investigational compound, zuranolone (SAGE-217; ZRN), two neuroactive steroid (NAS) GABAA receptor positive allosteric modulators, were eva...

Samantha Meltzer-Brody , MD;

Handan Gunduz-Bruce , MD, MBA;

Helen Colquhoun , MD;

Kristina Deligiannidis , MD;

Stephen Kanes , MD, PhD;

10/08/2020

Hospitalization Risk among Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics: A Long-Term Retrospective Analysis of Medicaid Claims Data

Objective: To compare the risk of hospitalization for adults with bipolar I disorder (BPD-I) when treated with lurasidone vs. other atypical antipsychotics (AAPs) as monotherapy.

Jason Shafrin , PhD;

Carole Dembek , MS;

Xiaoli Niu , PhD;

Phani Veeranki , MD, DrPH;

Syvart Dennen , MS;

Yanmei Liu , MS;

Kimberly Laubmeier , PhD;

G.R. Williams , PhD;

10/08/2020

Non-Healthcare Societal Burden of Schizophrenia Among Veterans

Introduction: Schizophrenia (SCZ) is a severe mental disorder imposing substantial healthcare burden to society. Data quantifying the non-healthcare societal burden of SCZ is limited, esp...

Carmella Benson , MSc, MS, MSHP;

Hyunchung Kim ;

Maya Aboumrad , MPH;

Keiko Wada ;

Ethan Powell , BA;

Gabrielle Zwain , BA;

Aimee Near ;

Dee Lin , PharmD, MS;

10/08/2020

Good, moderate, and poor functioning of adult patients with schizophrenia treated with aripiprazole once-monthly or paliperidone palmitate once-monthly in the Qualify study

Introduction QUALIFY was a 28-week, randomized, open-label, rater-blinded, head-to-head study (NCT01795547) evaluating effectiveness of aripiprazole once-monthly (AOM 400) vs paliperidone...

Simon Nitschky Schmidt , PhD;

Lizbeth Arias , MD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

10/08/2020

Medication Adherence, Healthcare Resource Utilization, and Costs Among Medicaid Beneficiaries With Schizophrenia Treated With Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate

Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Kruti Joshi , MPH, MD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Aurelie Cote ;

Maude Vermette-Laforme , BSc;

10/08/2020

Functioning in de novo and rollover patients with bipolar I disorder receiving aripiprazole once-monthly in a 52-week, open-label study

Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults...

Maxine Chen , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

10/08/2020

Measuring Antidepressant Primary Adherence Among Insured Patients With Major Depressive Disorder Using Linked Electronic Health Record and Administrative Claims Data

Major depressive disorder (MDD) is challenging to treat. Antidepressants are prescribed to manage symptoms; the first step toward effective treatment is for patients to fill their new pre...

Rachel Halpern , PhD;

Erin Buysman , MD;

Carolyn Martin , MSW;

Miriam Cisternas , MA;

Monica Frazer , MA, PhD;

10/08/2020

Impact of Lemborexant on Patient-Reported Insomnia-Related Worry/Distress and Interference With Daily Functioning Over 6 Months: Results From SUNRISE-2

INTRODUCTION: The insomnia severity index (ISI) is a self-report instrument that evaluates perception of insomnia severity. In Study 303 (SUNRISE-2), lemborexant (LEM) showed greater red...

Rakesh Jain , MD, MPH, RD;

Jane Yardley , PhD;

Kate Pinner , MSc;

Manoj Malhotra , MD;

Margaret Moline , PhD;

Norman Atkins Jr., MBA, PhD;

Craig Chepke , MD, DFAPA;

10/08/2020

Long-term Efficacy of Lurasidone in Pediatric Bipolar Depression: Post-hoc Analysis of Response, Remission and Recovery

Background: The aim of this analysis was to evaluate the long-term efficacy of lurasidone in achieving response and remission in children and adolescents with bipolar depression.

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Manpreet Singh , MD, MS;

Edward Schweizer , MD;

10/08/2020

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products